Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024

Contributed by: Business Wire

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

Kyowa Kirin

More Like This

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome

Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)

Polish Ministry of Health Approves Reimbursement of POTELIGEO® (mogamulizumab) for Adults Living With Mycosis Fungoides or Sézary Syndrome

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome